N/A
N=6
tDCS to Lower Neuropathic Pain and Fatigue in People With Multiple Sclerosis
Multiple Sclerosis
Bottom Line
View on ClinicalTrials.gov: NCT03870048 ↗Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Aug 2022
Primary outcome: Primary: Neuropathic Pain Questionnaire (NPQ) Contains 12 Items. — 21.3; 10.3 Points
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- transcranial direct current stimulation (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Iowa
- Primary completion
- Mar 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Neuropathic Pain Questionnaire (NPQ) Contains 12 Items. |
21.3; 10.3 | — |
| SECONDARY Fatigue Severity Scale (FSS) Contains Nine Statements That Attempt to Explore Severity of Fatigue Symptoms. |
4; 6 | — |
Summary
The purpose of this study is to investigate the effects of transcranial direct current stimulation (tDCS) on neuropathic pain and fatigue in people with MS. The investigators will conduct tDCS or sham on 5 consecutive days. They will evaluate pain and fatigue with specific questionnaires and measure fatigability with an isokinetic device.
The research question is whether tDCS can lessen neuropathic pain and increase fatigue resistance in people with MS. It is hypothesized, that less neuropathic pain and increased fatigue resistance after the tDCS sessions.
Eligibility Criteria
Inclusion Criteria
- Medically diagnosed with Multiple Sclerosis
- 18-70 yrs. of age, moderate disability (Patient Determined Disease Steps (PDDS) core 2-6)
- Self-reported differences in function between legs
- Able to walk for 6 min
- Presenting with chronic, drug-resistant, neuropathic pain.
Exclusion Criteria
- Relapse within last 60 days
- High risk for cardiovascular disease (ACSM risk classification)
- Changes in disease modifying medications within last 45 days
- Concurrent neurological/neuromuscular disease
- Hospitalization within last 90 days
- Diagnosed depression
- Inability to understand/sign informed consent.
Data sourced from ClinicalTrials.gov (NCT03870048). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.